IC95%: 0.65-0.83) 59
No clinical trial has tested cagrilintide + tirzepatide together in humans
Understanding your individual oxidative stress markersmeasured through biomarkers like 8-OHdG or lipid peroxidescan help guide whether glutathione peptide support aligns with your specific cellular health needs

Lillys eloralintide (amylin receptor agonist), providing a potential option for Lilly to defend against amylin analogues, including Novo Nordisks CagriSema, which combines dual amylin and calcitonin receptor agonist cagrilintide and semaglutide, or Zealands petrelintide (phase 2) Structure Therapeutics GSBR-1290 (GLP-1), small molecule, oral obesity therapy, seeking to substantiate its earlier, positive phase 2a data to deliver competitive weight loss, against both other oral therapies and marketed injectables, with acceptable tolerability (phase 2b) Crucially, a number of phase 3 readouts in 2025 for key AOM assets will set the stage for their launch in 2026, when the next wave of AOMs enter the market to re-shape the competitive landscape: Lillys orforglipron (GLP-1), one of the first oral AOMs to launch, possibly alongside oral semaglutide, and when it does, the first small molecule based therapy in the market

If you are considering GLP-1 therapy for weight loss, we offer a free initial consultation to see if our program is right for you.
Overall, the guide is helpful and sets you up for success